Skip to content

Advertisement

Reviews

Section edited by Sandra Demaria, MD and Thomas F. Gajewski, MD, PhD

Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.

Page 1 of 2

  1. Content type: Review

    CD8+ T lymphocytes are the major anti-tumor effector cells. Most cancer immunotherapeutic approaches seek to amplify cytotoxic T lymphocytes (CTL) specific to malignant cells. A recently identified subpopulation ...

    Authors: Fathia Mami-Chouaib, Charlotte Blanc, Stéphanie Corgnac, Sophie Hans, Ines Malenica, Clémence Granier, Isabelle Tihy and Eric Tartour

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:87

    Published on:

  2. Content type: Review

    Cancer surgery is necessary and life-saving. However, the majority of patients develop postoperative recurrence and metastasis, which are the main causes of cancer-related deaths. The postoperative stress resp...

    Authors: Orneala Bakos, Christine Lawson, Samuel Rouleau and Lee-Hwa Tai

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:86

    Published on:

  3. Content type: Review

    Recent advances in our understanding of the dynamics of cellular cross-talk have highlighted the significance of host-versus-tumor effect that can be harnessed with immune therapies. Tumors exploit immune chec...

    Authors: Muhammad Umair Mushtaq, Athanasios Papadas, Adam Pagenkopf, Evan Flietner, Zachary Morrow, Sibgha Gull Chaudhary and Fotis Asimakopoulos

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:65

    Published on:

  4. Content type: Review

    During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific ...

    Authors: Alexander Shimabukuro-Vornhagen, Philipp Gödel, Marion Subklewe, Hans Joachim Stemmler, Hans Anton Schlößer, Max Schlaak, Matthias Kochanek, Boris Böll and Michael S. von Bergwelt-Baildon

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:56

    Published on:

  5. Content type: Review

    Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to ...

    Authors: Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar and Richard Tuli

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:46

    Published on:

  6. Content type: Review

    Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (F...

    Authors: Young Kwang Chae, Ayush Arya, Wade Iams, Marcelo R. Cruz, Sunandana Chandra, Jaehyuk Choi and Francis Giles

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:39

    Published on:

  7. Content type: Review

    Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and bio...

    Authors: Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George and Tian Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:4

    Published on:

  8. Content type: Review

    With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic optio...

    Authors: Adam Ajina and John Maher

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:90

    Published on:

  9. Content type: Review

    Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for...

    Authors: David H. Aggen and Charles G. Drake

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:94

    Published on:

  10. Content type: Review

    Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-maligna...

    Authors: Louise M.E. Janssen, Emma E. Ramsay, Craig D. Logsdon and Willem W. Overwijk

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:79

    Published on:

  11. Content type: Review

    The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particula...

    Authors: Ryan Slovak, Johannes M. Ludwig, Scott N. Gettinger, Roy S. Herbst and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:78

    Published on:

  12. Content type: Meeting report

    Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Soc...

    Authors: Andrew Zloza, A. Karolina Palucka, Lisa M. Coussens, Philip J. Gotwals, Mark B. Headley, Elizabeth M. Jaffee, Amanda W. Lund, Arlene H. Sharpe, Mario Sznol, Derek A. Wainwright, Kwok-Kin Wong and Marcus W. Bosenberg

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:77

    Published on:

  13. Content type: Review

    Therapeutic efforts to engage the immune system against cancer have yielded exciting breakthroughs and a growing list of approved immune-based agents across a variety of disease states. Despite the early succe...

    Authors: James L. Gulley, Elizabeth A. Repasky, Laura S. Wood and Lisa H. Butterfield

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:55

    Published on:

  14. Content type: Review

    The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 ...

    Authors: Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries and Dominik Rüttinger

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:53

    Published on:

  15. Content type: Review

    This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November...

    Authors: Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky Jr., Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:50

    Published on:

  16. Content type: Review

    As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic...

    Authors: Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton and Lisa H. Butterfield

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:44

    Published on:

  17. Content type: Review

    Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in ...

    Authors: David F. Stroncek, Lisa H. Butterfield, Michael A. Cannarile, Madhav V. Dhodapkar, Tim F. Greten, Jean Charles Grivel, David R. Kaufman, Heidi H. Kong, Firouzeh Korangy, Peter P. Lee, Francesco Marincola, Sergio Rutella, Janet C. Siebert, Giorgio Trinchieri and Barbara Seliger

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:21

    Published on:

  18. Content type: Review

    Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent yea...

    Authors: Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:16

    Published on:

  19. Content type: Review

    Established tumors build a stressful and hostile microenvironment that blocks the development of protective innate and adaptive immune responses. Different subsets of immunoregulatory myeloid populations, incl...

    Authors: Juan R. Cubillos-Ruiz, Eslam Mohamed and Paulo C. Rodriguez

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:5

    Published on:

  20. Content type: Review

    Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populatio...

    Authors: Jiwon S. Park, Sita S. Withers, Jaime F. Modiano, Michael S. Kent, Mingyi Chen, Jesus I. Luna, William T. N. Culp, Ellen E. Sparger, Robert B. Rebhun, Arta M. Monjazeb, William J. Murphy and Robert J. Canter

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:97

    Published on:

  21. Content type: Review

    Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolo...

    Authors: Hiep Khong and Willem W. Overwijk

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:56

    Published on:

  22. Content type: Meeting report

    Treatment strategies that target the immune system provide the opportunity for antitumor activity across multiple cancer types, regardless of mutational status or tumor histology. While many of the initial adv...

    Authors: Paolo Antonio Ascierto, Giacomo Cartenì, Cesare Gridelli, Sandro Pignata, Antonio Pinto, Carmen Criscitiello, Luigi Buonaguro, Stefano Pepe, Roberto Mabilia, Vincenzo Montesarchio, Bruno Daniele and Sabino De Placido

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:41

    Published on:

  23. Content type: Review

    The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically t...

    Authors: Holbrook E. Kohrt, Paul C. Tumeh, Don Benson, Nina Bhardwaj, Joshua Brody, Silvia Formenti, Bernard A. Fox, Jerome Galon, Carl H. June, Michael Kalos, Ilan Kirsch, Thomas Kleen, Guido Kroemer, Lewis Lanier, Ron Levy, H. Kim Lyerly…

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:15

    Published on:

  24. Content type: Review

    The culmination of over a century’s work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses i...

    Authors: Jianda Yuan, Priti S. Hegde, Raphael Clynes, Periklis G. Foukas, Alexandre Harari, Thomas O. Kleen, Pia Kvistborg, Cristina Maccalli, Holden T. Maecker, David B. Page, Harlan Robins, Wenru Song, Edward C. Stack, Ena Wang, Theresa L. Whiteside, Yingdong Zhao…

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:3

    Published on:

  25. Content type: Meeting report

    In this paper, we review recent advances in immuno-oncology with particular focus on liver, kidney, and bladder cancers as discussed at the 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO).

    Authors: Bruno Daniele, Bruno Sangro, Daniel Petrylak, Fabio Calabrò, Giacomo Cartenì, Vincenzo Montesarchio, Sabino De Placido and Paolo A. Ascierto

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:1

    Published on:

  26. Content type: Review

    Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. ...

    Authors: Yong Wha Moon, Joud Hajjar, Patrick Hwu and Aung Naing

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:51

    Published on:

  27. Content type: Review

    The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently...

    Authors: Leila Khoja, Marcus O. Butler, S. Peter Kang, Scot Ebbinghaus and Anthony M. Joshua

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:36

    Published on:

  28. Content type: Meeting report

    The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. ...

    Authors: Abigail E. Overacre, Sema Kurtulus, Mario Sznol, Drew M. Pardoll, Ana Anderson and Dario A. A. Vignali

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:38

    Published on:

  29. Content type: Review

    Tumor-specific immunotherapy holds the promise of eradicating malignant tumors with exquisite precision without additional toxicity to standard treatments. Cancer immunotherapy has conventionally relied on cel...

    Authors: Elias J Sayour, Luis Sanchez-Perez, Catherine Flores and Duane A Mitchell

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:13

    Published on:

  30. Content type: Review

    Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offe...

    Authors: Cariad Chester, Oliver Dorigo, Jonathan S Berek and Holbrook Kohrt

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:7

    Published on:

  31. Content type: Review

    Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. Th...

    Authors: Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, Sanjiv S Agarwala, Ahmad A Tarhini, James N Lowder and Michael B Atkins

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:26

    Published on:

  32. Content type: Review

    Antibodies targeting T-cell inhibitory pathways, such as CTLA-4 and PD-1/PD-L1, are emerging as an important class of cancer therapeutics, and a next generation of immunomodulatory therapies targeting alternat...

    Authors: Ross Stewart, Scott A Hammond, Michael Oberst and Robert W Wilkinson

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:29

    Published on:

  33. Content type: Commentary

    Authors: Camilo E Fadul, Jan L Fisher, Thomas H Hampton and Marc S Ernstoff

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:22

    Published on:

  34. Content type: Commentary

    Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering real-world implementation practices, and their evolution over time. Modern cancer therapeutics...

    Authors: Michael K Wong, Howard L Kaufman, Gregory A Daniels, David F McDermott, Sandra Aung, James N Lowder and Michael A Morse

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:20

    Published on:

  35. Content type: Review

    The 28th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held November 8–10, 2013 in National Harbor MD, and was organized by Paolo Ascierto (Instituto Nazionale Tumori – Fondazione 'G. Pa...

    Authors: Paolo A Ascierto, David H Munn, Anna K Palucka and Paul M Sondel

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:15

    Published on:

  36. Content type: Review

    Knowledge of the basic mechanisms of the immune system as it relates to cancer has been increasing rapidly. These developments have accelerated the translation of these advancements into medical breakthroughs ...

    Authors: Raju R Raval, Andrew B Sharabi, Amanda J Walker, Charles G Drake and Padmanee Sharma

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:14

    Published on:

  37. Content type: Review

    In 2012, it was estimated that 9180 people in the United States would die from melanoma and that more than 76,000 new cases would be diagnosed. Surgical resection is effective for early-stage melanoma, but out...

    Authors: Howard L Kaufman, Carl E Ruby, Tasha Hughes and Craig L Slingluff Jr

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:11

    Published on:

  38. Content type: Meeting report

    Investigators from academia and industry gathered on April 4 and 5, 2013, in Washington DC at the Arrowhead’s 2nd Annual Cancer Immunotherapy Conference. Two complementary concepts were discussed: cancer “stem ce...

    Authors: Adrian Bot, Maurizio Chiriva-Internati, Andrew Cornforth, Brian J Czerniecki, Soldano Ferrone, Kenneth Geles, Philip D Greenberg, Elaine Hurt, Richard C Koya, Masoud H Manjili, William Matsui, Richard A Morgan, Claudia M Palena, Daniel J Powell Jr, Nicholas P Restifo, David M Spencer…

    Citation: Journal for ImmunoTherapy of Cancer 2014 2:6

    Published on:

  39. Content type: Research article

    The development of immuno-oncologic agents poses unique challenges, namely that both efficacy and safety profiles differ from previously characterized cytotoxic and pathway-specific agents. In addition, expone...

    Authors: Tai-Tsang Chen

    Citation: Journal for ImmunoTherapy of Cancer 2013 1:18

    Published on:

2017 Journal Metrics

Advertisement